Bellerophon provides clinical program update and reports third quarter 2020 financial results

Warren, n.j., nov. 05, 2020 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results for the third quarter ended september 30, 2020.

BLPH Ratings Summary

BLPH Quant Ranking